Omics Data Integration for Immune Therapy Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune therapies using checkpoint inhibition, vaccines, and cell-based compositions face challenges in predicting treatment success due to variability in patient responses, with existing methods failing to accurately predict outcomes for all cancer types.
Innovation Solution
Computational analysis of omics data from tumors to identify APOBEC and POLE mutational signatures, MSI status, and immune checkpoint expression, which are integrated to generate a patient profile predicting therapeutic outcomes for immune therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibition therapy is administered to treat cancer, then immune response is enhanced, but prediction of treatment success remains inaccurate
Solution Approach 1:
The patent segments the predictive system into three distinct components: (1) detection of mutational signatures (APOBEC, POLE, polymerase eta) in tumor DNA, (2) assessment of immune checkpoint expression levels, and (3) integration of these data to generate a predictive score. This segmentation allows each component to be independently validated and optimized, improving overall prediction reliability without overwhelming complexity
Solution Approach 2:
The patent develops a universal predictive system that can be applied across multiple cancer types by identifying common mutational signatures and immune checkpoint mechanisms. The same analytical framework (sequencing + expression analysis + integration) is used universally, while accommodating cancer-type specific variations in mutational patterns and checkpoint expression
2Measurement precision
If multiple biomarkers are analyzed to improve prediction accuracy, then treatment outcome prediction improves, but analysis complexity increases
Solution Approach 1:
The patent merges multiple independent biomarker assessments (mutational signature detection, MSI status, immune checkpoint expression levels) into a single integrated predictive model. Rather than analyzing each marker separately, the system combines them into a unified score that reflects their combined predictive value, simplifying the overall interpretation while maintaining high precision
Solution Approach 2:
The patent transforms complex multi-dimensional biomarker data into a simplified predictive parameter by establishing threshold values and weighting schemes. Mutational signatures are detected through sequencing depth and frequency patterns, immune checkpoint expression is quantified relative to normal tissue, and these parameters are integrated using established algorithms to produce a single predictive output
Data Source
AI summary
Systems and methods for prediction of the treatment outcome for immune therapy are presented in which omics data of a patient tumor sample are used. Most typically, the omics data are processed to identify mutational signatures (especially APOBEC/POLE signatures), immune checkpoint expression, and MSI status as leading indicators to predict the treatment outcome for immune therapy. Such prediction advantageously integrates various parameters that would otherwise, when individually considered, skew prediction outcome.